NCT01567813 is a clinical trial in Human Papilloma Virus Infection, sponsored by Merck Sharp & Dohme LLC.

Who is sponsoring NCT01567813?

NCT01567813 is sponsored by Merck Sharp & Dohme LLC.

What condition does NCT01567813 study?

NCT01567813 studies Human Papilloma Virus Infection.

Is NCT01567813 still recruiting?

NCT01567813 is currently completed. Last updated 22 July 2022.

Last reviewed 2022-07-22 · How we verify

NCT01567813

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Post-Licensure Study of the Safety of GARDASIL™ in Males (V501-070)

Completed Last updated 22 July 2022

What this trial tests

trial in Human Papilloma Virus Infection in 114,035 participants. Completed in 1 June 2019.

Timeline

23 June 2011

Primary endpoint
1 June 2019

1 June 2019

Quick facts

Lead sponsor	Merck Sharp & Dohme LLC
Status	Completed
Study type	OBSERVATIONAL
Enrollment	114,035
Start date	23 June 2011
Primary completion	1 June 2019
Estimated completion	1 June 2019

Conditions studied

Human Papilloma Virus Infection — all drugs for Human Papilloma Virus Infection →

Sponsor

Merck Sharp & Dohme LLC — full company profile →

Who can join

Adults 9 to 26, male only, with Human Papilloma Virus Infection. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a post-licensure safety observation cohort study to describe the general safety of GARDASIL™ (a quadrivalent human papillomavirus vaccine) in males.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Human papillomavirus vaccination: a case study in translational science.
Palmer AK, Harris AL, Jacobson RM. · · 2014 · cited 4× · PMID 24841923 · DOI 10.1111/cts.12166

Verify or expand the search:

Other recruiting trials for Human Papilloma Virus Infection

Currently open trials in the same condition.

NCT06467942 — Effects of Chinese Medicine and Lactobacillus in Persistent HPV Infection · NA · recruiting

Other Merck Sharp & Dohme LLC trials

Trials by the same sponsor.

NCT07224477 — A Clinical Study of V540A in Healthy Female Participants (V540A-005) · Phase 2 · not yet recruiting
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT07528508 — A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527 · Phase 1 · not yet recruiting
NCT07513376 — A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (M · Phase 3 · not yet recruiting
NCT07532304 — A Clinical Trial of MK-4646 With Bictegravir/Emtricitabine/Tenofovir Alafenamide and Dolutegravir in Healthy Adult Parti · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01567813 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Merck Sharp & Dohme LLC
Last refreshed: 22 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01567813.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing